Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Profit After Tax (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Profit After Tax for 7 consecutive years, with -$237.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 131.87% year-over-year to -$237.1 million, compared with a TTM value of -$684.6 million through Dec 2025, down 112.42%, and an annual FY2025 reading of -$684.6 million, down 112.42% over the prior year.
  • Profit After Tax was -$237.1 million for Q4 2025 at Avidity Biosciences, down from -$174.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$23.8 million in Q1 2021 and bottomed at -$237.1 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$75.6 million, with a median of -$52.4 million recorded in 2023.
  • The sharpest move saw Profit After Tax crashed 291.85% in 2021, then decreased 2.92% in 2023.
  • Year by year, Profit After Tax stood at -$38.5 million in 2021, then crashed by 30.96% to -$50.5 million in 2022, then dropped by 19.76% to -$60.4 million in 2023, then tumbled by 69.18% to -$102.3 million in 2024, then tumbled by 131.87% to -$237.1 million in 2025.
  • Business Quant data shows Profit After Tax for RNA at -$237.1 million in Q4 2025, -$174.4 million in Q3 2025, and -$157.3 million in Q2 2025.